Delving into the Latest Updates on Levocarnitine propionate hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

L-Carnitine propionate, Levocarnitine propionate hydrochloride (USAN), Levocarnitine proprionate

+ [10]

Target

PDHK

Mechanism

PDHK stimulants(Pyruvate dehydrogenase kinase stimulants)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Peripheral Vascular Diseases

Inactive Indication

Colitis, UlcerativeHeart FailureIntermittent Claudication+ [3]

Originator Organization

Sigma-Tau BV

Active Organization-

Inactive Organization

Sigma-Tau Industrie Farmaceutiche Riunite SpA

Lee's Pharmaceutical Holdings Ltd.

Hefei Zhaofeng Keda Pharmaceutical Co., Ltd. Guangzhou Branch

+ [1]

Drug Highest PhaseApproved

First Approval Date

IT (01 Jan 1998),

Heart FailurePeripheral Vascular Diseases

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H20ClNO4

InChIKeyKTFMPDDJYRFWQE-DDWIOCJRSA-N

CAS Registry119793-66-7

The effects on the stress response, postanesthetic sedation, and altered behavior were evaluated following regional anesthesia and dental treatment in 40 dogs. Serum cortisol and blood glucose concentrations were measured following the administration of levobupivacaine (LBUP) 0.5% and dexmedetomidine (DEX) (0.5 µg/kg) or a placebo. The dogs were randomly assigned to 4 groups of 10 dogs each. All dogs received a regional nerve block using LBUP 0.5%. Group 1 (LBUP + DEX IV) also received DEX intravenously (IV); group 2 (LBUP + PLC IV) also received a placebo IV; group 3 (LBUP + DEX IO) also received DEX in one infraorbital (IO) block; and group 4 (LBUP + DEX IA) also received DEX in one inferior alveolar (IA) block. Serum cortisol and blood glucose concentrations were determined before the administration of oral blocks and at the end of the procedure. Sedation and behavior scores were assessed before premedication and hourly for 6 h after the end of anesthesia. Cortisol concentration did not change in any group at either evaluation time. The glucose concentration was higher ( P < .05) only in the LBUP + DEX IA group at the end of the procedure. The sedation score was higher until the end of the observation period only in the LBUP + DEX IV and LBUP + PLC IV groups. No change in behavior score was observed in any of the groups. The reduction of perioperative stress response in all groups was due to the use of LBUP and not DEX.

01 Dec 2024·Psychiatry Research

Sex differences in response to intranasal oxytocin as an adjunctive therapy for patients with severe mental illness

Article

Author: Grossman-Giron, Ariella ; Sedoff, Omer ; Maoz, Hagai ; Tzur Bitan, Dana ; Bitan, Dana Tzur ; Baruch, Noam ; Mama, Yaniv ; Nitzan, Uri

Studies investigating the potential benefits of intranasal oxytocin (INOT) as an add-on treatment for patients with severe mental illness (SMI) have yielded inconsistent results, potentially due to sex differences in response to INOT. This study explored the differential effects of INOT among male and female patients with SMI. A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI. Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks. Sex moderated the effect of OT/PLC on the Hamilton Rating Scale for Depression (HRDS) (p < 0.001). A significant effect for sex was found in the Hopkins Symptom Checklist-short form (HSCL-11) (p = 0.04) and HRDS (p < 0.001), with females showing greater reductions in anxiety and depression symptoms and severity. This effect was not found for males. We conclude that the addition of INOT to the treatment of patients with SMI in an inpatient setting was beneficial for female patients, particularly reducing depressive symptoms, but not for male patients. Future studies should aim to identify patients who are more likely to benefit from INOT administration.

01 Dec 2024·Journal of Dairy Science

Prepartum anti-inflammatory therapies in Holstein dairy cows blocked by parity and body condition score group: Effects on metabolic stress, systemic inflammation, performance, and health

Article

Author: Lawhead, J. ; Sorto, R. ; Hovingh, E. ; Barragan, A A ; Spring, J ; Barragan, A.A. ; Jimenez, E ; Hovingh, E ; Zarei, P. ; Martinez, M ; Martinez, M. ; Lawhead, J ; Sorto, R ; Zarei, P ; Lection, J ; Lection, J. ; Jimenez, E. ; Spring, J.

The objective of this study was to assess the effects of prepartum administration of anti-inflammatory therapies on BCS, BHB concentration, haptoglobin (HP) concentration, milk yield, milk components, rumination time, clinical health events, and reproductive performance in Holstein dairy cows. At 14 d before the expected calving date, cows (parous [PAR]; n = 170) and heifers (nulliparous [NUL]; n = 63) were blocked by BCS group (optimal [OPT] = 3-3.5; over-conditioned cows [OVERC; BCS ≥3.75 points]) and parity (NUL; PAR) and randomly allocated to 1 of 3 treatment groups: (1) ASA (n = 78): receive one oral administration of acetylsalicylic acid (4 boluses; 480 grain/bolus); (2) MEL (n = 76): receive one oral administration with meloxicam (1 mg/kg BW), or (3) PLC (n = 77): receive one oral treatment with gelatin capsules filled with water. Body condition score was assessed, and blood samples were collected, weekly starting 1 wk before treatment until 3 wk after calving. Daily milk yields and daily rumination times were collected from on-farm computer records. Dairy Herd Improvement Association monthly test data were collected to assess milk yield, SCC, and milk components. Furthermore, health events, culling rate, and reproductive performance data were collected from on-farm computer records. The data were analyzed using MIXED, GLIMMIX, and LIFETEST procedures of SAS as a randomized complete block design. On average, MEL-NUL cows produced 4.77 ± 0.93 kg/d and 4.81 ± 0.92 kg/d more milk from wk 6 to 21 of lactation compared with ASA-NUL and PLC-NUL cows, respectively. Similarly, a week by treatment by body condition group interaction was present, where OVERC cows treated with MEL produced more milk from wk 10 to 15 of lactation compared with ASA-OVERC and PLC-VERC cows. Parous cows treated with ASA had lower BCS compared with PAR cows treated with MEL or PLC. A lower percentage of OVERC cows treated with ASA became sick in the first 60 DIM compared with MEL-OVERC and PLC-OVERC cows (ASA = 23.88% ± 7.26%, MEL = 46.36% ± 8.57%; PLC = 46.74% ± 8.53%). Parous cows treated with ASA had a higher hazard ratio to become pregnant by 300 DIM compared with PAR MEL cows. Although the study was not sized for finding treatment differences in blocking criteria groups, these results suggest that treatment with prepartum anti-inflammatory therapies may have positive effects on milk yield and postpartum health in specific groups of cows, such as NUL and OVERC cows, although it may not be recommended for other animal categories, such as parous cows and cows with optimal BCS. Larger studies are needed to strengthen the associations observed in this study.

100 Deals associated with Levocarnitine propionate hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04713	-	A16AA01	DB15980

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Peripheral Vascular Diseases	IT	-	01 Jan 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 3	EU	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Kidney Diseases	Phase 3	EU	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Peripheral arterial occlusive disease	Phase 3	US	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Peripheral Arterial Disease	Discovery	CN	Lee's Pharmaceutical Holdings Ltd.	01 May 2008
Intermittent Claudication	Discovery	US	Alfasigma SpA	01 Apr 2006
Peripheral Vascular Diseases	Discovery	US	Alfasigma SpA	01 Apr 2006
Peripheral arterial occlusive disease	Discovery	US	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2022	Not Applicable	Head and Neck Neoplasms	150	L-carnitine 500mg	(nxrvvtpaul) = jlnpeokpib vjaaisnzdh (riadooyazg )	-	10 Sep 2022
				L-carnitine (Control)	(nxrvvtpaul) = znffvnanuo vjaaisnzdh (riadooyazg )
NCT01107730 (CTgov)	Phase 3	Atrial Fibrillation	33	L-carnitine (L-Carnitine)	lgqypymlga(ubygesjefb) = bnpimceesz qzjzclyxxq (ztscnapnwi, edmwevmnzf - xevisieocg) View more	-	13 May 2015
				Vitamin C (Vitamin C)	lgqypymlga(ubygesjefb) = llvqurdmvl qzjzclyxxq (ztscnapnwi, oypzmucyko - ofxapomsaz) View more
NCT00399919 (Pubmed \| J Cardiopulm Rehabil Prev)	Phase 3	Peripheral Arterial Disease	69	Propionyl-L-carnitine	wgoebwymbt(mqqwiauwkm) = rzkcilnpzn sfqfbjakcp (gnreusbmnt )	-	01 Mar 2011
				Placebo	wgoebwymbt(mqqwiauwkm) = drxncwmkkn sfqfbjakcp (gnreusbmnt )